Respiratory
Latest news
198 articles · 20 / page
Adjunctive Corticosteroids in Severe Pneumocystis jirovecii Pneumonia Among HIV-negative Patients: Insights from a Multicentre Randomised Trial
A multicentre randomized trial evaluated adjunctive corticosteroids in HIV-negative severe Pneumocystis jirovecii pneumonia, showing a non-significant reduction in 28-day mortality and no safety concerns, and calls for further targeted rese
Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial
The endTB-Q trial assessed the efficacy and safety of a shortened BDLC regimen versus WHO standard care in rifampicin-resistant and fluoroquinolone-resistant tuberculosis, finding BDLC non-inferior in mITT but overall not non-inferior, high
Mepolizumab in Preventing COPD Exacerbations in Patients with Eosinophilic Phenotype: Insights from the MATINEE Trial
Mepolizumab significantly reduces moderate to severe COPD exacerbations in patients with elevated eosinophils on triple inhaled therapy, marking a promising advance for eosinophilic COPD management.
High-Flow Nasal Oxygen Reduces Hypoxaemia During Bronchoscopy in COPD: Insights from the PROSA 2 Randomised Trial
The PROSA 2 trial demonstrates that high-flow nasal oxygen significantly reduces hypoxaemia time and events compared to conventional low-flow oxygen in COPD patients undergoing bronchoscopy, improving procedural safety without compromising
Decoding COPD Heterogeneity: Airway Eosinophilia, Type 2 Inflammation, and Corticosteroid Responsiveness
This study elucidates that airway eosinophilia in COPD is linked to enhanced type 2 inflammation in airway epithelium and predicts responsiveness to inhaled corticosteroids, revealing a distinct COPD endotype with potential for precision th
Low-Dose Morphine in COPD: Balancing Breathlessness Relief Against Sleep-Related Respiratory Risks
A randomized crossover trial reveals low-dose morphine in COPD does not improve sleep efficiency or breathlessness but may cause nocturnal hypoventilation, raising safety concerns despite unchanged next-day alertness.
Dupilumab Enhances Quality of Life and Relieves Respiratory Symptoms in COPD Patients with Type 2 Inflammation: Insights from BOREAS and NOTUS Trials
Add-on dupilumab significantly improves health-related quality of life and respiratory symptoms in COPD patients with type 2 inflammation, according to pooled results from the BOREAS and NOTUS phase 3 trials.
Sustained Alterations in Glutamate Metabolism After Resistance Exercise in Older Adults With COPD and Healthy Controls
Resistance exercise induces prolonged increases in glutamate production in older adults with COPD and healthy controls, highlighting unique metabolic adaptations that may influence pulmonary rehabilitation outcomes and muscle health.
Targeting IL-33 in COPD: Insights from the Phase 2a FRONTIER-4 Trial of Tozorakimab
The FRONTIER-4 phase 2a trial evaluated tozorakimab, an anti-IL-33 monoclonal antibody, in moderate-to-severe COPD with chronic bronchitis. While the primary endpoint was unmet in the overall population, efficacy signals emerged in patients
Decoding Thoracoabdominal Asynchrony in Severe COPD: Insights Into Exercise Limitation and Respiratory Support
This study reveals how thoracoabdominal asynchrony (TAA) during exercise reflects lung function severity and predicts breathlessness in very severe COPD patients, highlighting its potential to guide personalized respiratory support strategi
Enhancing Home Non-Invasive Ventilation Outcomes Through Real-World Telemonitoring: Insights from the eVENT Randomised Study
The eVENT study demonstrates that telemonitoring combined with remote support significantly improves arterial CO2 control and home NIV adherence compared to usual care, highlighting a promising approach to optimize chronic respiratory failu
Riociguat Continuation After Balloon Pulmonary Angioplasty Preserves Exercise Capacity in Inoperable CTEPH: Insights from the THERAPY-HYBRID-BPA Trial
The THERAPY-HYBRID-BPA study demonstrates that continuing riociguat after balloon pulmonary angioplasty maintains exercise capacity in patients with inoperable chronic thromboembolic pulmonary hypertension without increasing adverse events.
Enhancing Hospitalist Care of Undifferentiated Dyspnea with Cardiopulmonary Point-of-Care Ultrasonography: Reducing Length of Stay and Costs
Implementation of cardiopulmonary POCUS in hospitalist management of undifferentiated dyspnea significantly reduces hospital length of stay and costs, though adoption remains limited, highlighting the need for sustained training and support
Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications
The SOOTHE phase 2b trial demonstrates that camlipixant, a P2X3 antagonist, significantly reduces cough frequency and improves quality of life in refractory chronic cough patients, with a favorable safety profile, supporting its potential a
Bexotegrast Shows Promise in Treating Idiopathic Pulmonary Fibrosis: Insights from the INTEGRIS-IPF Phase 2a Trial
The INTEGRIS-IPF trial demonstrates that bexotegrast is well tolerated and may reduce lung function decline in IPF patients, offering hope for a novel antifibrotic therapy.
Optimizing Pyrazinamide Dosing in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Large Phase 3 Trial
A comprehensive analysis from the TBTC Study 31/ACTG A5349 reveals that flat dosing of pyrazinamide at 1,000 mg daily optimizes efficacy and safety, challenging current weight-banded dosing strategies for drug-susceptible tuberculosis.
Evaluating Germicidal UV Light to Reduce Respiratory Infections in Long-Term Care: Insights from a South Australian Randomized Trial
A randomized clinical trial in South Australian long-term care facilities found germicidal UV light appliances did not significantly reduce acute respiratory infection rates per cycle but modestly lowered total infections over time, suggest
Evaluating Carbocysteine in Mild-to-Moderate COPD: Insights From a Large Multicenter Controlled Trial
A large phase 4 trial found carbocysteine did not significantly reduce exacerbation rates or improve lung function in mild-to-moderate COPD, suggesting limited benefit beyond severe cases.
High-Dose vs Standard-Dose Influenza Vaccine in Older Adults: Insights from the DANFLU-2 Randomized Clinical Trial
The DANFLU-2 trial demonstrates that high-dose influenza vaccine reduces cardiovascular and cardiorespiratory hospitalizations compared to standard-dose in adults ≥65 years, with similar benefits across subgroups including heart failure and
Bivalent RSV Prefusion F Protein Vaccine: A Potential Strategy to Reduce Cardiovascular Hospitalizations in Older Adults
The DAN-RSV trial demonstrates that RSV vaccination significantly lowers all-cause cardiorespiratory hospitalizations among older adults, suggesting vaccines may reduce infection-triggered cardiovascular complications and benefit chronic di
Browse by specialty
Open language-specific specialty feeds and department pages.